Immunotherapeutics in Development for Prostate Cancer

被引：22

作者：

Harzstark, Andrea L. ^{[1
]}

Small, Eric J. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA

来源：

ONCOLOGIST | 2009年 / 14卷 / 04期

关键词：

Castration-resistant prostate cancer; GM-CSF; Immunotherapy; Phase II; PROSTVAC (TM); GVAX (R); Ipilimumab; Sipuleucel-T; COLONY-STIMULATING FACTOR; STEM-CELL ANTIGEN; PHASE-I TRIAL; INTERFERON-GAMMA; CTLA-4; BLOCKADE; DENDRITIC CELLS; GM-CSF; TUMOR-CELLS; NECK-CANCER; RHGM-CSF;

D O I：

10.1634/theoncologist.2008-0240

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer. This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti-cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy. The Oncologist 2009; 14: 391-398

引用

页码：391 / 398

页数：8

共 53 条

[1]

[Anonymous], 2008, J CLIN ONCOL, DOI DOI 10.1200/JCO.2008.26.15_SUPPL.5146

[2] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Parker, C ;

Skarupa, L ;

Pazdur, M ;

Panicali, D ;

Beetham, P ;

Tsang, KY ;

Grosenbach, DW ;

Feldman, J ;

Steinberg, SM ;

Jones, E ;

Chen, C ;

Marte, J ;

Schlom, J ;

Dahut, W .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269

[3] Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].

Bander, NH ;

Milowsky, MI ;

Nanus, DM ;

Kostakoglu, L ;

Vallabhajosula, S ;

Goldsmith, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601

[4]

BEER TM, 2008, J CLIN ONCOL S15, V28, P5004

[5] Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigenTARP [J].

Carlsson, B ;

Tötterman, TH ;

Essand, M .

PROSTATE, 2004, 61 (02) :161-170

[6]

*CELL GEN INC, CELL GEN COMPL PAT R

[7] Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase 2 trial of the cancer biotherapy research group [J].

Dillman, RO ;

Wiemann, M ;

Nayak, SK ;

deLeon, C ;

Hood, K ;

DePriest, C .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :367-373

[8]

DiPaola RS, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-1

[9]

DISIS ML, 2006, IMMUNOTHERAPY CANC, P1

[10] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

← 1 2 3 4 5 6 →